Status
Conditions
Treatments
About
BACKGROUND: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been questioned and remains undetermined in the immuno-oncology era. Results from the two randomized trials, CARMENA and SURTIME, have questioned the role and timing of the surgery in these patients, however, these trials have only used the targeted therapy, sunitinib. With the advent of more effective systemic therapies including immune checkpoint inhibitors (ICIs), the role of surgical therapy should be reexamined.
RATIONALE: The therapeutic effects of ICIs have demonstrated improved oncological outcomes compared to sunitinib. The updated results reported the beneficial role of upfront and deferred CN approach for selected patients. No studies have formally investigated the role of CN in the immune-oncology era where combinatorial use of CN plus ICIs might be beneficial.
HYPOTHESIS: Upfront or deferred CN will improve oncological outcomes (overall survival, and progression free survival) in patients with synchronous mRCC and ≤3 IMDC risk features compared to immune checkpoint inhibitors (nivolumab plus ipilimumab combination) alone.
This is an open, randomized, multicenter comparison trial, designed to evaluate the effect of the potential role of CN in combination with immunotherapy in mRCC patients with IMDC intermediate and poor risk.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Core needle biopsy proven metastatic renal cell carcinoma - clear cell histologic subtypes only acceptable.
Synchronous metastatic renal cell carcinoma with the primary tumor present in the kidney.
Patient must be willing to provide their human-derived materials.
Age ≥19.
Signed written informed consent obtained prior to any study specific procedures.
Patient must be willing and able to comply with the protocol.
Measurable disease as per RECIST v 1.1
Life expectancy of greater than 4 months.
Patients with more than one prognostic factor by the International Metastatic RCC Database Consortium (IMDC) criteria (intermediate- or poor-risk group).
Patients for which Nivolumab/Ipilimumab considered indicated according to the recommendations by the national health authorities. The prescription of nivolumab/ipilimumab in the circumstances of the study is considered as a standard treatment.
Karnofsky Performance status ≥70
Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.
Fertile women of childbearing potential (<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).
The required laboratory values are as follows:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 3 patient groups
Loading...
Central trial contact
Won Sik Ham
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal